证券代码：301207 证券简称：华兰疫苗 公告编号：2025-029 华兰生物疫苗股份有限公司 第二届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华兰生物疫苗股份有限公司（以下简称"公司"）第二届董事会第十五次会议 于2025年6月13日以电话或网络通讯方式发出通知，于2025年6月20日在公司会议 室以现场结合通讯表决方式召开，会议由董事长安康先生主持，会议应出席董事 9名，实际出席董事9名。会议的召集和召开符合《公司法》和《公司章程》的有 关规定。 为全面贯彻落实最新法律法规要求，确保公司治理与监管规定保持同步，进 一步规范公司运作机制，提升公司治理水平，根据《上市公司章程指引》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等最新法律法规、规范性文件的要求，公司结 合实际经营情况，对现行公司部分治理制度进行了修订和完善。 1、会议以 9 票同意，0 票反对，0 票弃权的表决结果通过了《关于修订〈公 司章程〉及其附件并办理工商变更登记的 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-028 华兰生物疫苗股份有限公司 关于开立闲置募集资金现金管理专用结算账户的公告 华兰生物疫苗股份有限公司（以下简称"公司"或"华兰疫苗"）于2025年2月28日 召开了第二届董事会第十二次会议、第二届监事会第十次会议，审议通过了《关于 继续使用部分闲置募集资金进行现金管理的议案》，公司董事会同意在确保不影响 募集资金投资项目建设和公司正常生产经营的前提下，继续使用不超过人民币10亿 元闲置募集资金进行现金管理，现金管理有效期自董事会审议通过之日起12个月内 有效。在上述额度和期限内，资金可循环滚动使用。同时公司董事会授权公司管理 层在额度范围内行使该项投资决策权并签署相关协议及办理相关具体事宜。具体内 容详见公司于2025年3月1日在巨潮资讯网披露的《关于继续使用部分闲置募集资金 进行现金管理的公告》（公告编号：2025-006）。 近日，为更好地进行现金管理，公司开立了闲置募集资金现金管理专用结算账 户，本次开立的账户具体信息如下： | 序号 | 账户名称 | 开户机构 | 账号 | | --- | --- | --- | --- | | 1 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-027 华兰生物疫苗股份有限公司 2024年年度权益分派实施公告 3、本次权益分派实施后除权除息参考价=（除权除息日前一日收盘价-按公司总 股本折算的每股现金红利）=除权除息日前一日收盘价-0.1979942 元/股。 【注：根据相关要求，此项数据保留七位小数，最后一位直接截取，不四舍五 入。】 一、股东大会审议通过利润分配方案情况 1、2025 年 4 月 25 日，华兰生物疫苗股份有限公司（以下简称"公司"）召开 2024 年度股东大会审议通过了《关于 2024 年度利润分配的议案》：公司当前总股本为 601,027,500 股，剔除公司回购专用证券账户中已回购股份 6,027,467 股后为 595,000,033 股，公司以 595,000,033 股为基数向全体股东每 10 股派现金股利 2 元 （含税），共计 119,000,006.60 元；本年度不送红股、不以资本公积转增股本。分配 现金红利后剩余未分配利润 2,175,468,168.32 元滚存至下一年度。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华兰生物疫苗股份有限公司（以下简称 "公司"）定于 2025 年 5 月 22 日（周四）15:25-16:55 参加在全景网举办的河南 辖区上市公司 2025 年投资者网上集体接待日活动，本次活动将采用网络远程的 方式举行，投资者可登录"全景·路演天下"（http://rs.p5w.net）参与本次互动交 流。 出席本次网上集体接待日活动的人员有：公司财务总监兼董事会秘书路珂先 生，证券事务代表李伦先生，欢迎广大投资者积极参与。 特此公告。 华兰生物疫苗股份有限公司董事会 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-026 华兰生物疫苗股份有限公司 关于参加河南辖区上市公司 2025年投资者网上集体接待日活动的公告 2025 年 5 月 17 日 ...

Core Viewpoint - The bidding price for influenza vaccines in Shenzhen has reached a historical low, with the winning bid for a trivalent influenza vaccine set at 8 yuan per dose, significantly impacting the competitive landscape of the vaccine market [1][6]. Group 1: Bidding Results - The winning supplier, Fosun Yalifeng, won the bid for 1.6 million doses of the trivalent influenza vaccine at a price of 8 yuan per dose [1][6]. - Other bidders included Changchun Biological Products Institute and Beijing Kexing, with bids of 8.35 yuan and 8.8 yuan per dose, respectively, all below 9 yuan [1][6]. - In comparison, the winning bid for a similar vaccine in Zhejiang province was 9.4 yuan per dose, indicating a regional price disparity [4]. Group 2: Competitive Landscape - The price competition among vaccine manufacturers has intensified, with many players in the market leading to price reductions as a key competitive factor [6][8]. - The scoring criteria for the bidding process included price, technical aspects, business components, integrity, and overall strength, with price accounting for 30% of the total score [6][8]. - The price war has also affected the financial performance of related companies, with significant profit declines reported, such as a 76% drop in net profit for Hualan Biological and a widening loss for Jindike [9].

Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

Core Viewpoint - The company, Hualan Biological Engineering Inc., has released its first quarter report for 2025, ensuring the accuracy and completeness of the financial information disclosed, with no significant omissions or misleading statements [1][2]. Financial Data Summary - The first quarter report has not been audited [3][7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - Non-recurring gains and losses include a refund of handling fees [3]. - The company confirms that there are no instances of classifying non-recurring gains and losses as recurring [3]. Shareholder Information - As of the reporting period, the total number of ordinary shareholders is not disclosed, but the company holds 6,027,467 shares in a repurchase account, representing 1.00% of total shares, ranking fifth among the top ten shareholders [5].

前十大流通股东累计持有： 6373.06万股，累计占流通股比： 44.97%，较上期变化： -66.00万 股。 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0551 | 0.0643 | -14.31 | 0.2349 | | 每股净资产（元） | 10.06 | 10.51 | -4.28 | 13.99 | | 每股公积金(元) | 4.87 | 4.87 | 0 | 7.74 | | 每股未分配利润(元) | 3.87 | 4.17 | -7.19 | 4.75 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.24 | 0.34 | -29.41 | 1.45 | | 净利润(亿元) | 0.33 | 0.39 | -15.38 | 0.94 | | 净资产收益率(%) | 0.54 | 0.61 | -11.48 | 1.70 | 数据四舍五入，查看更多财务数据> ...

Financial Performance - The company's revenue for Q1 2025 was ¥24,282,534.72, representing a decrease of 29.05% compared to ¥34,222,695.90 in the same period last year[5] - Net profit attributable to shareholders was ¥32,777,072.14, down 15.06% from ¥38,589,463.38 year-on-year[5] - Total operating revenue decreased to ¥24,282,534.72 from ¥34,222,695.90, representing a decline of approximately 29.1% year-over-year[17] - Net profit for the period was ¥32,777,072.14, down from ¥38,589,463.38, reflecting a decrease of approximately 15.1% year-over-year[18] - Basic earnings per share decreased by 14.31% to ¥0.0551 from ¥0.0643 in the same period last year[5] - Basic earnings per share decreased to ¥0.0551 from ¥0.0643, a decline of about 14.3% year-over-year[19] - Other income decreased to ¥2,558,547.64 from ¥3,545,030.98, a decline of about 27.9% year-over-year[18] Cash Flow - The net cash flow from operating activities was negative at -¥2,587,625.81, a decline of 102.68% compared to ¥96,429,081.13 in the previous year[5] - Cash inflow from operating activities totaled $224.24 million, a decrease from $494.88 million year-over-year[22] - Cash outflow related to operating activities was $226.83 million, compared to $398.45 million in the previous period[22] - Cash received from sales of goods and services was ¥214,904,356.36, down from ¥487,216,616.88, a decline of about 55.8% year-over-year[21] - Cash flow from financing activities showed a net outflow of -$30.66 million, compared to -$1.52 million in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,443,158,707.85, a decrease of 1.06% from ¥7,523,255,843.58 at the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 490,186,996.72 from CNY 623,035,019.91, reflecting a decline of approximately 21.3%[14] - Accounts receivable decreased to CNY 1,276,094,419.94 from CNY 1,437,459,795.12, indicating a reduction of about 11.2%[14] - The company’s long-term assets decreased to CNY 2,384,676,612.06 from CNY 2,546,736,316.68, a decline of approximately 6.4%[15] - Total liabilities decreased to ¥1,395,440,931.16 from ¥1,510,111,321.68, a reduction of approximately 7.6% year-over-year[16] - Total equity increased to ¥6,047,717,776.69 from ¥6,013,144,521.90, reflecting a growth of about 0.6% year-over-year[16] Expenses - Management expenses decreased by 37.18% to ¥7,947,905.52, mainly due to reduced equity incentive costs and employee benefits[8] - Research and development expenses increased to ¥22,115,565.91 from ¥19,022,504.10, an increase of approximately 16.4% year-over-year[18] - The company reported a 100.92% increase in financial expenses to ¥32,632.44, attributed to a decrease in interest income[8] Shareholder Information - The company has a total of 6,027,467 shares held in a repurchase account, accounting for 1.00% of total shares, ranking it as the 5th largest shareholder[12] - The company has a significant shareholder, CYBER CREATOR LIMITED, holding 8.98% of shares, indicating a strategic partnership[12] Government Support - The company received government subsidies amounting to ¥2,558,543.66, which are closely related to its normal business operations[6] Other Financial Metrics - The weighted average return on net assets was 0.54%, down from 0.61% in the previous year[5] - Deferred income tax liabilities decreased to ¥17,126,331.11 from ¥18,800,579.72, a reduction of approximately 8.9% year-over-year[16] - The impact of exchange rate changes on cash and cash equivalents was $55,928, contrasting with a negative impact of -$45,054 in the previous period[22]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-024 华兰生物疫苗股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、本次股东大会的召开时间： 现场会议召开时间为：2025 年 4 月 25 日下午 13:00 网络投票时间：2025 年 4 月 25 日。其中通过深圳证券交易所交易系统进行网 络投票的具体时间为 2025 年 4 月 25 日上午 9:15—9:25,9:30—11:30 和下午 13:00— 15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 4 月 25 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼会议 室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 5、现场会议主持人：董事长安康先生 6、本次股东大会的会议召集、召开程序符合有关法律、法 ...